The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Manipal Hospitals to use IBM Watson technology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

MANIPAL HOSPITALS’ corporate and teaching facilities in India will adopt IBM’s Watson for Oncology, a cognitive computing platform that analyzes data to identify evidence-based treatment options.

This will be the first deployment of Watson in India.

Watson for Oncology was developed by IBM in concert with Memorial Sloan Kettering Cancer Center. To date, Watson for Oncology has ingested nearly 15 million pages of medical content, including more than 200 medical textbooks and 300 medical journals. This year alone, nearly 44,000 oncology research papers have been published in medical journals around the world. This amounts to nearly 122 new papers published every day.

Table of Contents

YOU MAY BE INTERESTED IN

News Analysis

HHS presents new protein-forward dietary guidelines, turning the food pyramid upside down
The Kennedy guidelines are mum on cancer risks associated with red meat and alcohol

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
By Claire Marie Porter
Guest Editorial

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers

In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 
By Nicholas Richardson
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account